Please use this identifier to cite or link to this item:
Title: Liraglutide for type 2 diabetes mellitus.
Authors: Kela, R
Khunti, K
Davies, MJ
First Published: Jul-2011
Citation: EXPERT OPIN BIOL THER, 2011, 11 (7), pp. 951-959
Abstract: INTRODUCTION: Prevalence of type 2 diabetes mellitus (T2DM) is increasing. Management of this condition and minimizing the cardiovascular risks associated with it poses a significant burden on healthcare resources across the world. Currently available therapeutic agents are effective in glycemic management; however, the majority of these are associated with undesirable effects such as hypoglycemia and weight gain. Incretin-based therapies have been introduced over the last few years and are associated with less risk of hypoglycemia and weight gain. AREAS COVERED: This review includes current challenges in the management of T2DM, and an overview of glucagon-like peptide-1 (GLP-1)-based therapies, in particular the results of Phase III clinical studies of recently approved liraglutide. Apart from glycemic control, multifactorial interventions are needed to minimize the cardiovascular risks associated with T2DM. Liraglutide is effective in improving glycemic control measured by HbA1c and it is also shown to improve weight. Recently, the National Institute of Health and Clinical Excellence in the UK has approved liraglutide 1.2 mg dose in dual and triple therapy for T2DM. EXPERT OPINION: Liraglutide, a once-daily GLP-1 analog, has a definite role in selected patients with T2DM and the long-term cardiovascular safety is currently being ascertained in ongoing trials.
DOI Link: 10.1517/14712598.2011.583641
eISSN: 1744-7682
Type: Journal Article
Appears in Collections:Published Articles, Dept. of Cardiovascular Sciences

Files in This Item:
There are no files associated with this item.

Items in LRA are protected by copyright, with all rights reserved, unless otherwise indicated.